Safety and Tolerability of Combination Therapy with Ambrisentan and Tadalafil for the Treatment of Pulmonary Arterial Hypertension in Children: Real‐World Experience

2021 ◽  
Author(s):  
Azadeh Issapour ◽  
Benjamin Frank ◽  
Sarah Crook ◽  
Michelle D. Hite ◽  
Michelle L. Dorn ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Real World ◽  
Pulmonary Arterial ◽  
Hypertension In Children

scholarly journals Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database

2018 ◽  
Vol 9 (1) ◽  
pp. 204589401881629 ◽  
Author(s):  
Sean Studer ◽  
Michael Hull ◽  
Janis Pruett ◽  
Eleena Koep ◽  
Yuen Tsang ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Resource Utilization ◽  
Real World ◽  
Healthcare Resource ◽  
Healthcare Resource Utilization ◽  
Treatment Patterns ◽  
Combination Therapies ◽  
Pulmonary Arterial

Several new medications for pulmonary arterial hypertension (PAH) have recently been introduced; however, current real-world data regarding US patients with PAH are limited. We conducted a retrospective administrative claims study to examine PAH treatment patterns and summarize healthcare utilization and costs among patients with newly diagnosed PAH treated in US clinical practice. Patients newly treated for PAH from 1 January 2010 to 31 March 2015 were followed for ≥12 months. Patient characteristics, treatment patterns, healthcare resource utilization, and costs were described. Adherence (proportion of days covered), persistence (months until therapy discontinuation/modification), and the probability of continuing the index regimen were analyzed by index regimen cohort (monotherapy versus combination therapy). Of 1637 eligible patients, 93.8% initiated treatment with monotherapy and 6.2% with combination therapy. The most common index regimen was phosphodiesterase type 5 inhibitor (PDE-5I) monotherapy (70.0% of patients). A total of 581 patients (35.5%) modified their index regimen during the study. Most patients (55.4%) who began combination therapy did so on or within six months of the index date. Endothelin receptor agonists (ERAs) and combination therapies were associated with higher adherence than PDE-5Is and monotherapies, respectively. Healthcare utilization was substantial across the study population, with costs in the combination therapy cohort more than doubling from baseline to follow-up. The majority of patients were treated with monotherapies (most often, PDE-5Is), despite combination therapies and ERAs being associated with higher medication adherence. Index regimen adjustments occurred early and in a substantial proportion of patients, suggesting that inadequate clinical response to monotherapies may not be uncommon.

scholarly journals Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights

2015 ◽  
Vol 46 (2) ◽  
pp. 414-421 ◽  
Author(s):  
Fabio Dardi ◽  
Alessandra Manes ◽  
Massimiliano Palazzini ◽  
Cristina Bachetti ◽  
Gaia Mazzanti ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Real World ◽  
Survival Rates ◽  
Short Term ◽  
Real World Setting ◽  
Sequential Combination ◽  
Pulmonary Arterial ◽  
Heritable Pulmonary Arterial Hypertension

Pulmonary arterial hypertension is a severe disease with a complex pathogenesis, for which combination therapy is an attractive option.This study aimed to assess the impact of sequential combination therapy on both short-term responses and long-term outcomes in a real-world setting.Patients with idiopathic/heritable pulmonary arterial hypertension, or pulmonary arterial hypertension associated with congenital heart disease or connective tissue disease and who were not meeting treatment goals on either first-line bosentan or sildenafil monotherapy, were given additional sildenafil or bosentan and assessed after 3–4 months. Double combination therapy significantly improved clinical and haemodynamic parameters, independent of aetiology or the order of drug administration. Significant improvements in functional class were observed in patients with idiopathic/heritable pulmonary arterial hypertension. The 1-, 3- and 5-year overall survival estimates were 91%, 69% and 59%, respectively. Patients with pulmonary arterial hypertension associated with connective tissue disease had significantly poorer survival rates compared to other aetiologies (p<0.003).The favourable short-term haemodynamic results and good survival rates, observed in patients receiving both bosentan and sildenafil, supports the use of sequential combination therapy in patients failing on monotherapy in a real-world setting.

EFFECTIVENESS AND SAFETY OF COMBINATION THERAPY WITH AMBRISENTAN AND TADALAFIL FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION IN CHILDREN

2020 ◽  
Vol 75 (11) ◽  
pp. 2086
Author(s):  
Azadeh Issapour ◽  
Sarah Crook ◽  
Michelle Hite ◽  
Erika Berman Rosenzweig ◽  
Benjamin Frank ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Pulmonary Arterial ◽  
Hypertension In Children

scholarly journals EXPERIENCE WITH MACITENTAN TRIPLE COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION: REAL-WORLD EVIDENCE FROM THE OPUS REGISTRY

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A2217-A2219
Author(s):  
John McConnell ◽  
Kelly Chin ◽  
Nick Kim ◽  
Vallerie McLaughlin ◽  
Megan Flynn ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Combination Therapy ◽  
Arterial Hypertension ◽  
Real World ◽  
Triple Combination ◽  
Triple Combination Therapy ◽  
Real World Evidence ◽  
Pulmonary Arterial

scholarly journals 4CPS-223 Real world experience of selexipag for pulmonary arterial hypertension

2021 ◽  
Author(s):  
M Eguiluz Solana ◽  
C Martin Dominguez ◽  
R Bravo Marqués ◽  
JJ Arenas Villafranca ◽  
MI Saez Rodriguez ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Real World ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document